dMed, a Shanghai Clinical CRO, Opens Washington Office for US FDA Filings
publication date: Jun 20, 2019
dMed Biopharma, a Shanghai clinical CRO, has opened a Washington office to help China biopharmas complete their US regulatory filings. Since 2017, China's harmonization with the regulatory systems of other countries revolutionized the opportunities for China biopharmas, the company said. The number of US INDs filed by China biopharmas jumped from 11 in 2016 to 38 in 2018, a number that was equaled in the first quarter of 2019 alone. Among other things, the dramatic rise reflects the effect of numerous China-developed CAR-T candidates. dMed's Washington office is led by Dr. Eric Zhang, a former FDA reviewer. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.